Other languages Mendus AB

Equities

IMMU

SE0005003654

Delayed Nasdaq Stockholm Other stock markets 03:02:27 29/04/2024 pm IST			5-day change	1st Jan Change
0.469 ^SEK	-1.16%		-4.29%	-10.33%

16/04	Mendus AB Announces Board Changes	CI
27/03	Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mendus AB Announces Board Changes	16/04
Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	27/03
Mendus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/02
Mendus AB Announces Clinical Pipeline Update	22/12
Mendus AB Appoints Ted Fjällman as Board Member	13/12
Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023	12/12
Mendus AB and Australasian Leukaemia & Lymphoma Group to Expand Clinical Testing of Vididencel as Maintenance Treatment for AML	06/12
Mendus Announces appointment of Nomination Committee for the 2024 Annual General Meeting	17/11
Mendus AB Presents Updated Alison Clinical Trial Data for Vididencel in Ovarian Cancer At SITC 2023	06/11
Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal	03/11
Mendus AB Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data	02/11
Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23	21/23/21
Mendus Obtains US FDA's Fast Track Tag for Blood Cancer Therapy	08/23/08
Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia	08/23/08
Mendus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/23/29
Mendus AB Announces the Publication of Novel Preclinical Data on its Intratumoral Priming Strategy in the Peer-Reviewed Medical Journal 'Frontiers in Immunology	16/23/16
Mendus AB Appoints Lewis Lanier to Scientific Advisory Board	20/23/20
Sweden’s Mendus Receives European Medicines Agency Certification for Cancer Vaccine	20/23/20
Mendus AB Presents Comprehensive Advance II Immunomonitoring Data at the EHA Annual Meeting 2023	12/23/12
Eurozone's Q1 Recession Weigh on Most EU Markets Thursday	08/23/08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Mendus AB

Equities

IMMU

SE0005003654

Other languages

Filters